Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
In: CARDIOVASCULAR DIABETOLOGY, 2023, Heft 1
Online
academicJournal
Zugriff:
Background: We assessed whether hepatic steatosis with or without significant fibrosis (determined by validated non-invasive biomarkers) is associated with an increased 10-year estimated risk for cardiovascular disease (CVD) in people with type 1 diabetes mellitus (T1DM). Methods: We conducted a retrospective, multicenter, cross-sectional study involving 1,254 adults with established T1DM without pre-existing CVD. We used the hepatic steatosis index (HSI) and fibrosis (FIB)-4 index for non-invasively detecting hepatic steatosis (defined as HSI > 36), with or without coexisting significant fibrosis (defined as FIB-4 index ≥ 1.3 or < 1.3). We calculated the Steno type 1 risk engine and the atherosclerotic CVD (ASCVD) risk score to estimate the 10-year risk of developing a first fatal or nonfatal CVD event. Results: Using the Steno type 1 risk engine, a significantly greater proportion of patients with hepatic steatosis and significant fibrosis (n = 91) had a high 10-year estimated CVD risk compared to those with hepatic steatosis alone (n = 509) or without steatosis (n = 654) (75.8% vs. 23.2% vs. 24.9%, p < 0.001). After adjustment for sex, BMI, diabetes duration, hemoglobin A1c, chronic kidney disease, and lipid-lowering medication use, patients with hepatic steatosis and significant fibrosis had an increased 10-year estimated risk of developing a first fatal or nonfatal CVD event (adjusted-odds ratio 11.4, 95% confidence interval 3.54-36.9) than those without steatosis. We observed almost identical results using the ASCVD risk calculator. Conclusions: The 10-year estimated CVD risk is remarkably greater in T1DM adults with hepatic steatosis and significant fibrosis than in their counterparts with hepatic steatosis alone or without steatosis.
Titel: |
Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
|
---|---|
Autor/in / Beteiligte Person: | Mantovani, Alessandro ; Mario Luca Morieri ; Palmisano, Luisa ; Masulli, Maria ; Cossu, Efisio ; Marco Giorgio Baroni ; Bonomo, Katia ; Flavia Agata Cimini ; Cavallo, Gisella ; Buzzetti, Raffaella ; Mignogna, Carmen ; Leonetti, Frida ; Bacci, Simonetta ; Trevisan, Roberto ; Riccardo Maria Pollis ; Aldigeri, Raffaella ; Alessandra Dei Cas ; Saula Vigili de Kreutzenberg ; Targher, Giovanni ; Luca Morieri, Mario ; Baroni, Marco Giorgio ; Cimini, FLAVIA AGATA ; Maria Pollis, Riccardo ; Dei Cas, Alessandra ; Vigili de Kreutzenberg, Saula |
Link: | |
Zeitschrift: | CARDIOVASCULAR DIABETOLOGY, 2023, Heft 1 |
Veröffentlichung: | BMC ; London, 2023 |
Medientyp: | academicJournal |
DOI: | 10.1186/s12933-023-01945-x |
Schlagwort: |
|
Sonstiges: |
|